Elie Ghabi

Surgery Resident | IMG | Levantine | All Things Cancer and Digital Photography

[Alex C. Kim, MD, PhD @Alex_Kim_HIPEC]

Excited to share our new work in @JAMAOnc on early onset #colorectalcancer. https://t.co/1cdL8U5Xep

Using real-world data from last 20 years in Texas-one of the most diverse states in the US-we identified two key findings:

[Annals of Surgical Oncology @AnnSurgOncol]

#AudioVisualAbstract : Risk Factors for and Oncologic Impact of #AnastomoticLeakage After Sphincter-Preserving #Proctectomy for Mid/Low #RectalCancer : A Multi-institutional Cohort Study in Japan

https://t.co/PzVCC4T8o8

@AMVillanoMD
@SyedAAhmad5

[JAMA Surgery @JAMASurgery]

A systematic review found that hospital admissions for #Diverticulitis consistently peaked in warmer months and were lowest in winter across multiple continents, indicating environmental or behavioral influences on disease onset.

https://t.co/tqzPGVAbIm

[Hassan R. Hashmi, MD, FACS, DABS @HassanRHashmiMD]

Early detection of anastomotic leak saves lives.

A recent study published in @JAMASurgery highlights a critical reality in colorectal surgery. Delayed diagnosis of anastomotic leak significantly increases failure to rescue (FTR), meaning mortality after a complication.

The key message is clear. It is not just the complication, but also the timing of recognition that determines outcomes.

Patients with delayed diagnosis, especially after the onset of sepsis, had:

-Higher complication burden
-Increased reoperation rates
-Longer hospital stays
-Significantly higher mortality

As surgeons, this reinforces a fundamental responsibility. Vigilance in the postoperative period, early suspicion, and decisive intervention truly impact survival.

Improving systems for early detection of anastomotic leak and escalation of care are powerful quality improvement strategies which could improve mortality associated with colon resection.

#ColorectalSurgery #PatientSafety #QualityImprovement #Surgery #ClinicalExcellence #SurgicalOutcomes #EvidenceBasedMedicine

@ASCRS_1 @AmCollSurgeons @oncodaily @SoyColoproctoMX

[DCRjournal @DCRjournal]

Single institution series on long-term outcome of botox in the treatment of Crohn's fissure-in-ano. How successful is it? Read more in this month's #DCRJournal: https://t.co/k17DB3277U
@JyiChengNg; @RumerMDPhD; @Ibrahim_Gomaa95; @anupama679

[Syed A. Ahmad @SyedAAhmad5]

Early cancer detection in a large American Cancer Society cohort study: Retrospective analysis of methylated DNA biomarkers https://t.co/TUtN5JwIMm

[DCRjournal @DCRjournal]

#DCRJournal visual abstract recap | Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy: https://t.co/E2LB7qJHzS

@SeanLangenfeld @Schadi_CRS @slsteinmd1 @MarkSoliman @rahila_essani @JohnRTMonsonMD @SoniaRamMD

[Annals of Gastroenterological Surgery @surgery81261]

📢 HCC management in the systemic therapy era
🔹 Systemic therapy in the ICI era
🔹 Trends in conversion surgery
🔹 Oncological Resectability Criteria (R/BR1/BR2)
A concise review summarizing the current landscape of HCC management by surgeons and hepatologists 📖
Read more ➡️ https://t.co/OdYjcXsBvI
Sohei Satoi (KMU) / Daisuke Asano(Science Tokyo)
#AGSurg #HCC #ICI #ConversionSurgery #SoMe4Surgery @BJSAcademy @me4_so

[Annals of Gastroenterological Surgery @surgery81261]

Is NOSE a safe alternative for colon cancer surgery? This systematic review of 1,683 patients shows that while operative time is longer, NOSE significantly reduces blood loss and hospital stay. Most importantly, long-term oncological outcomes are comparable to conventional methods.
https://t.co/qnBibTGNFd
#AGSurg #colorectalresearch #colorectalsurgery

[BJS Open @BjsOpen]

Accuracy and variability of locoregional staging in T1 rectal cancer: nationwide multicentre cohort study
➡️https://t.co/2k0fxWElgd

There is no clear consensus on the optimal methods for locoregional staging of rectal polyps suspected to be T1 cancers. This study emphasizes the high variability in clinical practices and limitations of EUS and MRI in real-life clinical settings.

👏👏👏Maria Daca-Alvarez , Cristina Manzotti , Diana Zaffalon , Isabel Portillo , Luis Bujanda , Inés Gil-Lasa , Gemma Ibañez-Sanz , Xavier Sanjuan , Alberto Herreros-de-Tejada , Inmaculada Salces , Lara Aguilera , Marta Ponce , Ángeles Pizarro , David Barquero , Ignasi Puig , Pilar Diez Redondo , Fernando Martínez de Juan , Victor Jair Morales , Marco Alburquerque , Salvador Machlab , Angel Ferrandez , Beatriz Peñas , Alvaro Díaz-González , Lluïsa Sargatal , Rodrigo Jover , Luis Hernandez , Alberto Pérez Pedrosa , Eva Musulen , Goretti Hernandez , Marita Trelles , Akiko Ono , Jorge Lopez Vicente , Raquel Bravo , Juan R Ayuso , Angels Ginés , Karmele Saez de Gordoa , Miriam Cuatrecasas , Maria Pellisé , EpiT1 Consortium
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery #colorectalsurgery #colorectalcancer @FightCRC #StepUp4CRC

[Annals of Surgery @AnnalsofSurgery]

In a prospective multicenter trial of high-risk rectal cancer, TME with sphincter-sparing procedures demonstrated similar early outcomes across laparoscopic, robotic, and transanal approaches. https://t.co/dyik5dIiCP

[Michał Nedoszytko MD, PhD @mnedoszytko]

“Physicians building with Claude”. A live webinar organized by @AnthropicAI - join us on Thursday April 23rd at 10am PT

Together with @grahamwalker we will showcase our journeys of building for healthcare.

Daisy Sophia Hollman from Claude code team will join us to discuss how to use @claudeai and Claude Code to bring your next big ideas to life - while respecting safety, privacy and compliance.

Thank you @PollyIsrani and Neel Patel for organizing. Looking forward to this great event - register here!

https://t.co/REQV6uXYOF

@nosajab @bcherny

[Oscar Tahuahua @drtahuahua]

🚨 Up to 40% of rectal cancer patients may not need surgery.

In dMMR disease (with proper testing)
Immunotherapy → ~90-100% CR

In MSS
TNT: ~1 in 3 achieve cCR

With watch-and-wait:
~85% keep their rectum
>95% remain metastasis-free
Local regrowth ~15%, mostly detected early and successfully salvaged

It’s smarter upfront intensification then personalized decisions.

But this isn’t a simple algorithm.
It requires clinical judgment, proper testing, careful selection and intensive surveillance.

What once seemed unthinkable is now part of evolving clinical practice; the state of the art care
https://t.co/qM4gjtik8v

[Surgical Oncology Insight @SurgOncInsight]

March Issue: Robotic right #Hemicolectomy with complete mesocolic excision and D3 #Lymphadenectomy : Perioperative complications and oncologic outcomes

https://t.co/GIBTqkn0YQ

@FlavioRochaMD
@DrMikeCavnar
@SKMaithel
@HalletJulie
@JulietOkoroh
@TheNotoriousHPB
@AradhyaNigamMD

[BJS Open @BjsOpen]

Meta-core outcome set for randomized trials and clinical practice for curative surgical oncology: patient and healthcare consensus statement
➡️https://t.co/DwShOpsooi

This article describes the consensus-driven development process of a minimum set of outcomes that should be reported in cancer surgery trials across specialities. This does not detract from previous work within those specialities, but supplements them and, more importantly, assists in cancer trials where the cancer types are still without a core outcome set for reference.

👏👏👏Joel Tay , @BlazebyJ , Declan Devane , Yoon Loke , Aoife Lowery , Adam O’Neill , Catherine Robinson , Ceri Steele , @BilalAlkhaffaf, Jamie Kirkham
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery

[MV Chandrakanth @ChandrakanthMv]

Low rectum ≠ mid rectum.
Tumor location changes treatment goals.
Low rectum → organ preservation strategy (TNT + watch-and-wait).
Mid rectum → surgery-centered cure, radiation may be omitted.
A key concept highlighted in this JCO review. 👇
#MVOnco #RectalCancer #Oncology

[Dr. Foxpaws Fauxpas @foxpaws_onco]

Let's review #TNT Total Neoadjuvant Treatment and Organ Preservation in #Rectal #Cancers.

1. PRODIGE23 - Induction CT + CRT
2. PROSPECT - No RT & Mid/upper only
3. OPRA - Induction CRT CT Ph2
4. OPERA - Contact Brachy Boost
5. MORPHEUS - HDR BT boost

#crcsm
#Oncology